Acute autoimmune hepatitis after fingolimod discontinuation and glatiramer acetate starting in a Relapsing-Remitting Multiple Sclerosis patient

Mattioda A1, Chiavazza C1, Binello E1, Morgando A2, David E1, Vercellino M1, Pinessi L1, Cavalla P1

1 MS Center, Department of Neuroscience, University Hospital City of Health and Science of Turin, Italy
2 Division of Gastroenterology and Hepatology, University Hospital City of Health and Science of Turin, Italy
3 Pathology Department, University Hospital City of Health and Science of Turin, Italy

INTRODUCTION

An association has been described between multiple sclerosis (MS) and autoimmune hepatitis (AIH) (1). AIH has been reported in untreated MS patients (2) and in patients treated with Interferon-beta (BIFN) (3), Glatiramer Acetate (GA) (4) and Natalizumab (NTZ) (5, 6). Fingolimod (FTY) is an oral sphingosine-1-phosphate receptor modulator approved for Relapsing-Remitting Multiple Sclerosis (RR-MS) treatment. It appears attenuating certain immune cells in secondary lymphoid organs and preventing their infiltration of central nervous system (7). Increased alanine aminotransferase (ALT) values > 3 times the upper limit of normal is reported to occur in 8% of patients treated with FTY. The causes of hepatic effects are unknown and generally attributed to drug-induced liver injury (DILI).

In our case-report we describe in a MS patient: a) hepatic injury during FTY therapy (DILI), b) withdrawal of FTY and hepatic improvement, c) severe AIH following FTY discontinuation and GA starting.

CASE REPORT

We describe the case of a 52-year-old male patient suffering from MS since 2002. He had no further comorbidities except for cluster headache and hypertension; family history was negative for autoimmune diseases. At the time of MS diagnosis the presence of Anti-Nuclear Antibodies (ANA) at low titer (1:80) was demonstrated. He was first treated with BIFN-1a (Rebif 44 mcg) from May 2003 to July 2011; during this period he developed a trigeminal neuralgia which required chronic treatment with ox-carbazepine. During early BIFN therapy a mild liver enzymes increase was observed, that spontaneously recovered. In September 2011 NTZ was started because of incomplete recovery from clinical MS activity (with EDSS increase from 2.0 to 3.5). Liver function remained normal during NTZ therapy. NTZ was stopped in October 2013 (26 infusions) because of increased PML risk and FTY was started in January 2014. Concomitant medications (ongoing before FTY starting) included enalapril, baclofen, oxcarbazepine and pregabalin. After 10 months of FTY therapy (November 2014) laboratory findings showed a mild increase in ALT values (61 UI) and a marked increase in Gammaglutamyl Transferase (GGT; 496 UI) (see Fig.1). Total bilirubin, International Normalized Ratio (INR) and albumine were normal; hepatic ultrasound did not show any signs of parenchymal injury. Patient was asymptomatic for abdominal pain, nausea or vomiting; physical examination was normal. Treatment with FTY was stopped according to gastroenterologic advice, with an hypothesis of a FTY-induced DILI. After a short washout period, GA was started to prevent disease reactivation.

In April 2015 (five months after FTY discontinuation) a consistent elevation of transaminases (AST 321 U/l, ALT 782 U/l) and GGT (190 U/l) with ALT values > 3 times the upper limit of normal was reported. An association has been described between multiple sclerosis (MS) and autoimmune hepatitis (AIH) (1). MS patients treated with FTY. The causes of hepatic effects are unknown and generally attributed to drug-induced liver injury (DILI). In our case-report we describe in a MS patient: a) hepatic injury during FTY therapy (DILI), b) withdrawal of FTY and hepatic recovery, c) severe AIH following FTY discontinuation and GA starting.

DISCUSSION

An association has been described between MS and AIH (1). This patient was predisposed to autoimmune systemic phenomena, as demonstrated by fluctuating ANA title. In our case-report, a definite diagnosis of AIH, proved by both histological and serological findings and supported by optimal corticosteroids response, was demonstrated after FTY withdrawal and GA starting. Treatment with FTY was stopped according to gastroenterologic advice, with an hypothesis of a FTY-induced DILI. After a short washout period, GA was started to prevent disease reactivation.

In April 2015 (five months after FTY discontinuation) a consistent elevation of transaminases (AST 321 U/l, ALT 782 U/l) and GGT (190 U/l) was observed. Viral markers for Hepatitis B virus (HBV), Hepatitis C virus (HCV), Hepatitis A virus (HAV), Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV) were negative. Anti-Smooth Muscle Antibodies (ASMA), Anti-Liver/Kidney Micosome Antibodies (LKM), Anti-Mitochondrial Antibodies (AMA) and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) were negative, while ANA title was raised to 1:320, with homogeneous pattern; gamma-globulins were increased (Ig G 3046 mg/dl; normal 840-1660).

A liver biopsy was performed, which demonstrated a chronic hepatitis with diffuse hepatocellular inflammatory necrosis and plasma cells portal infiltrates. Numerous eosinophils were detected too. The histological features were consistent with AIH. Patient started corticosteroid therapy (intravenous methylprednisolone 80 mg for two days, followed by oral tapering with prednisone) with progressive normalization of liver enzymes, ANA and gamma-globulins levels. In August 2015 (one month after prednisone interruption) we observed a new increase of GGT (119 UI) and a positive ANA title (1:160, homogeneous pattern). Steroid treatment was resumed, GA was stopped and patient started on azathioprine (50 mg/day), which is still ongoing and well tolerated. One month after azathioprine introduction liver enzymes are normal and ANA title is negative.

REFERENCES

7. All authors have nothing to disclose

All authors have nothing to disclose

Corresponding author: paola.cavalla@unito.it